Compare Baxter International Inc (BAX) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Snowflake Inc — how do they compare? Baxter International Inc trades at $22.16 (market cap $11.26B), while Snowflake Inc trades at $272 (market cap $95.64B). The key difference: Snowflake Inc is far larger — about 8.5× Baxter International Inc's market cap, and Baxter International Inc pays a 0.92% dividend while Snowflake Inc pays none. Which is the better fit depends on your goals.
| BAX | SNOW | |
|---|---|---|
Market Cap | $11.26B | $95.64B |
Sector | Health | Technology |
52-Week High | $29.22 | $280.16 |
52-Week Low | $15.80 | $121.11 |
Enterprise Value | $18.93B | $95.46B |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
Snowflake (SNOW) trades at $268.65, up 2.75% with strong technical momentum and bullish moving average signals. The company demonstrates robust revenue growth, reaching $3.63 billion in 2025, though remains unprofitable with a -23.79% net margin. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $0.39 surpassing the $0.3193 estimate. Analyst sentiment remains overwhelmingly positive with 42 buy ratings and a $297.35 consensus price target, representing 10.7% upside potential.
Snowflake's outlook remains promising due to accelerating AI Data Cloud adoption and 30% revenue growth targets, but faces risks from premium valuation (P/S 18.19), intense cloud competition, and persistent profitability challenges. The stock's current technical positioning near pivot point resistance at $269 requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
